Stay updated with breaking news from Aduhelm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For those now grappling with Alzheimer's, lecanemab holds out the promise of slowing the disease's progress. Are the modest benefits worth the risks?
Death rates about the same in both groups. but it's going to end up being a discussion with the doctor, the patient, and the family if this gets approved and to really weigh those risk benefits. it may not be applicable to people on blood thinners. >> so, what's the process now? >> so, i mean, at this point, i think if it gets approved, so, the drug company is hoping that it will get accelerated approval in january and they will apply for full approval by april. then the big question is what happens when you roll it out in the real world. does that one point difference translate to something m...
US regulators approved CSL Behring’s haemophilia B gene therapy, a one-off infusion that frees patients from regular treatments but costs $3.5m a dose, making it the most expensive medicine in the world.
How to balance patient’s needs with their safety.
The answer is tied to Medicare and how seniors pay for it.